Elenae Therapeutics Analysis
What is Elenae Therapeutics?
AI-designed ASOs for heart, muscle, and retina
Location
Berkeley, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- AI-designed antisense oligonucleotides targeting heart, skeletal muscle, retina, and lung
- LNA mixmer ASOs with phosphorothioate backbone
- Subcutaneous delivery once-weekly to once-monthly
- Efficacy and safety data in mice, pigs, and non-human primates
Use Cases
Target microRNAs in heart failure; Treat dry age-related macular degeneration; Address aging-related sarcopenia; Manage Duchenne and Becker muscular dystrophies; Deliver ASOs to previously inaccessible tissues
Other Considerations
Founded by Anders M. Näär, PhD, UC Berkeley Professor of Metabolic Biology; Based in Bakar Labs biotech incubator at UC Berkeley; Early-stage clinical data in non-human primates and pigs; Employee count of 2-10; Founded in 2021
See something that needs updating? Suggest edits to this profile.